Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11565187 | 0.85 | OPRM1 (0.70) | OPRM1OPRD1CACNA1COPRK1 | |
| Oxalic Acid SCHEMBL6045761 | 0.83 | OPRM1 (0.67) | OPRM1OPRD1CACNA1COPRK1 | |
| Oxalic Acid SCHEMBL6045561 | 0.81 | OPRM1 (0.83) | OPRM1OPRD1CACNA1COPRK1 | |
| SCHEMBL6045500 | 0.80 | OPRM1 (0.69) | OPRM1OPRD1CACNA1COPRK1 | |
| Oxalic Acid SCHEMBL11563217 | 0.80 | OPRM1 (0.81) | OPRM1OPRD1CACNA1COPRK1 | |
| SCHEMBL11563016 | 0.79 | OPRM1 (0.57) | OPRM1OPRD1CACNA1COPRK1KDM4E | |
| SCHEMBL11565173 | 0.79 | OPRM1 (0.61) | OPRM1OPRD1CACNA1COPRK1 | |
| Oxalic Acid SCHEMBL6045521 | 0.78 | OPRM1 (0.61) | OPRM1OPRD1CACNA1COPRK1MEN1 | |
| SCHEMBL6045629 | 0.78 | OPRM1 (0.60) | OPRM1OPRD1CACNA1COPRK1 | |
| Oxalic Acid SCHEMBL6045565 | 0.78 | OPRM1 (0.55) | OPRM1OPRD1CACNA1COPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | OPRM1 148/4885OPRD1 180/4885CACNA1C 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.